Vincenzo Bagnardi

Vincenzo Bagnardi

Auto-generated profile, based on publicly available information

Vincenzo Bagnardi

Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
SKSabrina Kahler-Ribeiro-Fontana
Sabrina Kahler-Ribeiro-Fontana
EPEleonora Pagan
Eleonora Pagan
FRANCESCA MAGNONIFRANCESCA MAGNONI
FRANCESCA MAGNONI
EVElisa Vicini
Elisa Vicini
CMConsuelo Morigi
Consuelo Morigi
VGViviana Galimberti
Viviana Galimberti

17 January 2024 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
Matteo RotaMatteo Rota
Matteo Rota
IPIrene Possenti
Irene Possenti
VVValeria Valsassina
Valeria Valsassina
CSClaudia Santucci
Claudia Santucci
VBVincenzo Bagnardi
Vincenzo Bagnardi
ALAlessandra Lugo
Alessandra Lugo

6 October 2021 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
FLFrancesca De Lorenzi
Francesca De Lorenzi
FBFrancesco Borelli
Francesco Borelli
EPEleonora Pagan
Eleonora Pagan
VBVincenzo Bagnardi
Vincenzo Bagnardi
NPNickolas Peradze
Nickolas Peradze
PVPAOLO VERONESI
PAOLO VERONESI
Background: Oncoplastic surgery is a well-established approach that combines breast-conserving treatment for breast cancer and plastic surgery techniques. Although this approach already has been described for multicentric and multifocal tumors, no long-term oncologic follow-up evaluation and no comparison with patients undergoing mastectomy have been published. This study aimed to evaluate whether oncoplastic surgery is a safe and reliable treatment for managing invasive primary multicentric and multifocal breast cancer. Methods: The study compared a consecutive series of 100 patients with multicentric or multifocal tumors who had undergone oncoplastic surgery (study group) with 100 patients who had multicentric or multifocal tumors and had undergone mastectomy (control group) during a prolonged period. The end points evaluated were disease-free survival (DFS), overall survival (OS), cumulative incidence of local recurrence (CI-L), regional recurrence (CI-R), and distant recurrence (CI-D), all measured from the date of surgery. Results: The OS and DFS were similar between the two groups. The incidence of local events was higher in the oncoplastic group, whereas the incidence of regional events was slightly higher in the mastectomy group. These differences were not statistically significant. The cumulative incidence of distant events was similar between the two groups. Conclusions: To the authors’ knowledge, the current study provides the best available evidence suggesting that the oncoplastic approach is a safe and reliable treatment for managing invasive multifocal and multicentric breast cancers.

4 October 2023 in HPB
Verified
Journal Article
Closed access
CCchristian cotsoglou
christian cotsoglou
SGStefano Granieri
Stefano Granieri
SBSerena Bassetto
Serena Bassetto
VBVincenzo Bagnardi
Vincenzo Bagnardi
RPRaffaele Pugliese
Raffaele Pugliese
GPGiacomo Pugliese
Giacomo Pugliese

27 May 2008 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
EME Montagna
E Montagna
VBV Bagnardi
V Bagnardi
NRN Rotmensz
N Rotmensz
JRJ Rodriguez
J Rodriguez
PVPAOLO VERONESI
PAOLO VERONESI
MCmarco colleoni
marco colleoni
Locally advanced breast cancer (LABC) is associated with dire prognosis despite progress in multimodal treatments. We evaluated several clinical and pathological features of patients with either noninflammatory (NIBC, cT4a-c) or inflammatory (IBC, cT4d) breast cancer to identify subset groups of patients with high risk of early treatment failure. Clinical and pathological features of 248 patients with LABC, who were treated with multimodality treatments including neoadjuvant chemotherapy followed by radical surgery and radiotherapy were reassessed. Tumour samples obtained at surgery were evaluated using standard immunohistochemical methods. Overall, 141 patients (57%) presented with NIBC (cT4a-c, N0-2, M0) and 107 patients (43%) with IBC (cT4d, N0-2, M0). Median follow-up time was 27.5 months (range: 1.6–87.8). No significant difference in terms of recurrence-free survival (RFS) (P=0.72), disease-free survival (DFS) (P=0.98) and overall survival (OS) (P=0.35) was observed between NIBC and IBC. At the multivariate analysis, patients with ER- and PgR-negative diseases had a significantly worse RFS than patients with ER- and/or PgR-positive diseases (hazard ratio: 2.47, 95% CI: 1.33–4.59 for overall). The worst RFS was observed for the subgroup of patients with endocrine nonresponsive and HER2-negative breast cancer (2-year RFS: 57% in NIBC and 57% in IBC) A high Ki-67 labelling index (>20% of the invasive tumour cells) and the presence of peritumoral vascular invasion (PVI) significantly correlated with poorer RFS in overall (HR 2.69, 95% CI: 1.61–4.50 for Ki-67>20% and HR 2.27, 95% CI: 1.42–3.62 for PVI). Patients with endocrine nonresponsive LABC had the most dire treatment outcome. High degree of Ki-67 staining and presence of PVI were also indicators of higher risk of early relapse. These factors should be considered in therapeutic algorithms for LABC.

17 June 2021 in Updates in Surgery
Verified
Journal Article
Open access
PDF file
LRLorenzo Ripamonti
Lorenzo Ripamonti
RCRiccardo De Carlis
Riccardo De Carlis
Andrea LauterioAndrea Lauterio
Andrea Lauterio
IMI. Mangoni
I. Mangoni
SFSamuele Frassoni
Samuele Frassoni
LCL. De Carlis
L. De Carlis
Introduction: We sought to evaluate the effect of age on postoperative outcomes among patients undergoing major liver surgery for perihilar cholangiocarcinoma (PHCC). Methods: 77 patients were included. Patients were categorized into two groups: the “< 70-year-olds” group (n = 54) and the “≥ 70-year-olds” group (n = 23). Results: Median LOS was 19 both for < 70-year-old group and ≥ 70-year-old group (P = 0.72). No differences in terms of severe complication were detected (44.4% Clavien–Dindo 3–4–5 in < 70-year-old group vs 47.8% in ≥ 70-year-old group, P = 0.60). Within 90 postoperative days, 11 patients died, 6 in < 70-year-old group (11.3%) and 5 in ≥ 70-year-old group (21.7%), P = 0.29. The median follow‐up was 20 months. The death rate was 72.2% and 78.3% among patients < 70 years old and ≥ 70 years old. The OS at 2 and 5 years was significantly higher among the < 70 years old (57.0% and 27.7%) compared to the ≥ 70 years old (27.1% and 13.6%), P = 0.043. Adjusting for hypertension and Charlson comorbidity index in a multivariate analysis, the HR for age was 1.93 (95% CI 0.84–4.44), P = 0.12. Relapse occurred in 43 (81.1%) patients in the < 70-year-old group and in 19 (82.6%) patients in the ≥ 70-year-old group. DFS at 12, 24, and 36 months was, respectively, 59.6, 34.2, and 23.2 for the < 70 -year-old group and 32.5, 20.3, and 13.5 for the ≥ 70-year-old group (P = 0.26). Adjusting for hypertension and Charlson comorbidity index in a Cox model, the HR for age was 1.52 (95% CI 0.67–3.46), with P = 0.32. Conclusions: ≥ 70-year-old patients with PHCC can still be eligible for major liver resection with acceptable complication rates and should not be precluded a priori from a radical treatment.